DOCSLIB.ORG

Enzymes (Inhibition, Regulation, Isoenzymes & Specificity) Drarun Kumar K Enzyme Inhibition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enzymes (Inhibition, Regulation, Isoenzymes & Specificity) Drarun Kumar K Enzyme Inhibition Enzymes (Inhibition, regulation, isoenzymes & specificity) DrArun Kumar K Enzyme Inhibition Enzyme activity is decreased by certain compounds known as inhibitors. The process is called enzyme inhibition. 1.Competitive Inhibition 2.Non competitive inhibition 3.Uncompetitive inhibition 4.Suicide inhibition 5.Allosteric inhibition 1. Competitive inhibition • Competition b/w substrate and inhibitor for substrate binding site. • Inhibitor is a structural analogue of substrate. • E+I EI ; No product • Reversible. Can be reversed by increasing substrate conc. • Increased Km, No change in V max. • Example : Succinate dehydrogenase inhibited by Malonate Examples for Clinical Applications of Competitive Inhibition (drugs) • 1)Allopurinol – Xanthine Oxidase (Gout). • 2) Dicumarol – Vitamin K Epoxide reductase (Anticoagulant) • 3) Sulfonamide- Pteroid synthase (Antibiotic) • 4) Methotrexate & Aminopterin- Dihydrofolate reductase (Anticancer drug) • 5) Neostigmine –Acetyl cholinesterase (Myasthenia Gravis) • 6) Lovastatin – HMG CoA Reductase, (Hypercholesterolemia) • 7) Succinyl choline: Acetyl choline esterase (muscle relaxation in surgery) • 8) Ephidrene, Amphetamine: Mono Amino Oxidase (Hypotension) • 9) Ethanol in methanol poisoning: Alcohol Dehydrogenase. Noncompetitive Inhibition • There is no competition. • Inhibitor is not a structural analogue. • binds to site other than active site. • Generally Irreversible. Can not be reversed by increasing substrate concentration. • V Max decreased ; Km unchanged. Examles for noncompetitive inhibition (poisons) Cyanide – Cytochrome oxidase Diisopropyl fluorophosphate (DIFP) - Acetylcholinesterase. Fluoride- Enolase Iodoacetate : -SH enzymes (Glyceraldehdye 3- phosphate Dehydrogenase). 3. Uncompetitive Inhibition • Inhibitor Binds only to ES (not to free enzyme). • Both Km and V Max decreased. • Example : Inhibition of placental alkaline phosphatase by Phenylalanine. Suicide Inhibition (Mechanism based inactivation) • Structural analog of the substrate is converted to a more effective inhibitor by the action of the enzyme to be inhibited. • This new inhibitor formed irreversibly binds to the enzyme and inhibits it. • Irreversible inhibition. • Examples: • 1) Allopurinol (→Alloxanthine) – Xanthine oxidase Hypoxanthine ---→ xanthine • 2) Aspirin (anti inflammatory agent) - cyclooxygenase. Arachidonic acid ----→ prostaglandins. • 3) Di Fluoro Methyl Ornithine (DFMO- treatment of trypanosomiasis) –Ornithine Decarboxylase Ornithine -----→ Putrescine 5. Allosteric inhibition • Type of enzyme regulation. Enzyme regulation • Activity of certain can be increased or decreased depending on the need of the cell. • These enzymes are called Regulatory enzymes. • Types: • 1. Allosteric regulation • 2. Covalent modification • 3. Induction • 4. Repression. Allosteric Regulation (Allos = other) SUBSTRATE BINDING SITE ALLOSTERIC SITE ALLOSTERIC ENZYME 1. Allosteric Regulation (Allos = other) • Allosteric enzyme has a site other than catalytic site known as allosteric site. • It is for modifiers to bind. • The binding of the regulatory molecule can either • enhance the activity of the enzyme – allosteric activation, or • inhibit the activity of the enzyme - allosteric inhibition. Allosteric activation • The binding of the regulatory molecule to allosteric site enhances activity of the enzyme. • The modifier is called- positive modifier. ALLOSTERIC ENZYME ALLOSTERIC ACTIVATOR Phosphofructokinase AMP & Fructose 2,6 Bis hosphate Aspartate transcarbamoylase ATP Pyruvate carboxylase Acetyl CoA Acetyl CoA-carboxylase Citrate Carbamoyl phosphate N- Acetyl Glutamate synthetase I Allosteric inhibition • The binding of regulatory molecule to allosteric site decreases activity of the enzyme. • The modifier is negative modifier. • When an inhibitor binds to allosteric site, • configuration of catalytic site is modified • such that substrate cannot bind properly. • The inhibitor is not a substrate analog. • It is partially reversible, when excess substrate is added. • Km is usually increased, Vmax is reduced ALLOSTERIC ENZYME ALLOSTERIC INHIBITOR Phosphofructokinase ATP & Citrate Aspartate transcarbamoylase CTP Pyruvate carboxylase ADP Acetyl CoA-carboxylase Acyl CoA Carbamoyl phosphate UTP synthetase II feedback inhibition or end-product inhibition – activity of the enzyme is inhibited by the final product of the biosynthetic pathway. 2. Covalent modification • It is a type of enzyme regulation. • There is either addition of a group to the enzyme by forming a covalent bond; or • removal of a group by cleaving a covalent bond. • Types: i. Irreversible ii. Reversible i. Irreversible covalent modification • Activation of enzyme by breaking a covalent bond present the enzyme. • Once activated cannot be converted back to original inactive form. • Examples • Zymogen activation by partial proteolysis. Partial Proteolysis PROENZYME ACTIVE ENZYME + POLYPEPTIDE Peptide bond PROENZYMES / ACTIVE ENZYMES ZYMOGENS 1 PEPSINOGEN PEPSIN 2 TRYPSINOGEN TRYPSIN 3 CHYMOTRYPSINOGEN CHYMOTRYPSIN 4 PROELASTASE ELASTASE ii. Reversible covalent modification • By Addition or removal of a group such as i. phosphate group (phosphorylation– dephosphorylation) – (most common). ii. ADP-ribose group (rare) Pi ATP PROTEIN PHOSPHATASE PROTEIN KINASE Dephosphorylation Phosphorylation ADP H20 Enzyme Phosphorylated form Acetyl-CoA Inactive carboxylase Glycogen synthase Inactive Pyruvate Inactive dehydrogenase HMG CoA Inactive reductase Pyruvate kinase Inactive Phosphorylated form is Inactive Enzyme Phosphorylated form Glycogen Active phosphorylase Phosphorylase b Active kinase HMG CoA Active reductase kinase Phosphorylated form is Active 3. Induction • Process of increasing rate of synthesis of enzyme in the presence of inducer. • Induction is effected through the process of derepression. • The inducer will relieve the repression on the operator site and • will remove the block on the biosynthesis of the enzyme molecules. Inducible inducer enzyme 1 Tryptophan glucocorticoids pyrrolase 2 transaminase glucocorticoids 3 Glucokinase insulin 4 ALA barbiturates synthase 4. Repression • Process of decreasing rate of synthesis of enzyme in the presence of repressor. • Examples: • ALA synthase is repressed by heme. • HMG CoA reductase is repressed by Cholesterol. • Inhibition by the end product of the pathway is called FEEDBACK Inhibition Isoenzymes • Multiple (physically distinct) forms of the same enzyme which catalyze the same reaction but differ in • Physical • Chemical • Immunoloical properties and • Electrophoretic mobilities. Types of isoenzymes 1. Product of different genes (true isoenzymes) 2. Which differ in subunit composition. 3. Which differ in prosthetic group composition (iso-forms). 1. Product of different genes Example: Salivary amylase and Pancreatic amylase 2. Which differ in subunit composition Example: i. Creatine kinase ii. Lactate Dehydrogenase(LDH). 3. Isoenzymes which differ in prosthetic group composition. • Example: • Alkaline Phosphatase (ALP) • ALP hydrolyzes compounds containing phosphate under alkaline condition (optimum pH is between 9 and 10). • Zinc is a constituent ion of ALP • Contains sialic acid as prosthetic group. Separation of isoenzymes 1. Agar gel or polyacrylamide gel electrophoresis. 2. Difference in Heat stability. 3. Using Inhibitors. 4. Difference in affinity for substrate 5. Using Specific antibodies Enzyme specificity • Enzymes are specific in their action. • 4 types: 1. Absolute specificity 2. Group specificity 3. Bond specificity 4. Stereospecificity 1. Absolute specificity • Enzymes which show absolute specificity are specific about - (a) their substrate and - (b) type of reaction. Example: 1. Urease catalyzes hydrolysis of Urea. 2. Glucose oxidase catalyzes oxidation of glucose. 2. Group specificity • These enzymes are specific about a particular group present in their substrate. • Example: 1. Hexokinase can add phosphate to - glucose, - galactose and - mannose. 3. Bond specificity • Are specific about a particular bond present in their substrate. • Example: 1. Trypsin hydrolyzes peptide bonds of any protein - hydrolyzes internal peptide bonds involving carboxyl groups of arginine or lysine residues. 2. Chymotrypsin – internal peptide bond - Phe and Tyr 4. Stereospecificity • These enzymes are specific about stereo isomeric form of their substrate. • Example: 1. Hexokinase acts only on D- Glucose 2. Transaminases act only on L- Amino acids. The activity of an enzyme is also sensitive to the presence of specific chemicals that bind to the enzyme. When the binding of the chemical shuts off enzyme activity, the process is called _________ and the chemical is called an _________ . (a) activation, activator (b) inhibition, inhibitor (c) Inhibition, promoter (d) activation, inhibitor Inhibition of succinate dehydrogenase by malonate is an example of (a) Non-competitive inhibition (b) Negative feed back (c) Allosteric inhibition (d) Competitive inhibition Which one of the following statement is incorrect? (a) A competitive inhibitor reacts reversibly with the enzyme to form an enzyme inhibitor complex (b) In competitive inhibition, the inhibitor molecule is not chemically change by the enzyme (c) The competitive inhibitor does not affect the rate of breakdown of the enzyme subtract complex (d) The present of the competitive inhibitor decreases the Km of the enzyme for the substrate. Suicidal Enzyme is: a. Lipoxygenase b. Cyclooxygenase c. Thromboxane Synthase d. 5’ Nucleotidase Noncompetitive enzyme inhibition leads to: a. Vmax ↑ b. Vmax ↓ c. Vmax unchanged d. Km ↑ e. Km ↓ True about competitive inhibition of enzyme: a. ↑ Km b. ↓ Km c. ↑ Vmax d. No change in Km and Vmax e. Vmax remain same Noncompetitive reversible inhibitors: a. Raise Km b. Lower Km c. Lower Vmax d. Raise both Vmax and Km. e. Do not affect either Vmax or Km Km changes and Vmax remains the same. What is the type of Enzyme inhibition? a. Competitive Inhibition b. Noncompetitive Inhibition c. Uncompetitive inhibition d. Suicide Inhibition Chymotrypsinogen is a: a. Zymogen b. Carboxypeptidase c. Transaminase d. Exopeptidase Trypsin is a: a. Serine protease b. Lecithinase c. Phospholipase d. Elastase.
Load more

Recommended publications
  • The Serpintine Solution
    & Experim l e ca n i t in a l l C C f a Journal of Clinical & Experimental o r d l i a o n l o r g u Lucas et al., J Clin Exp Cardiolog 2017, 8:1 y o J Cardiology ISSN: 2155-9880 DOI: 10.4172/2155-9880.1000e150 Editorial Open Access The Serpintine Solution Alexandra Lucas, MD, FRCP(C)1,2,*, Sriram Ambadapadi, PhD1, Brian Mahon, PhD3, Kasinath Viswanathan, PhD4, Hao Chen, MD, PhD5, Liying Liu, MD6, Erbin Dai, MD6, Ganesh Munuswami-Ramanujam, PhD7, Jacek M. Kwiecien, DVM, MSc, PhD8, Jordan R Yaron, PhD1, Purushottam Shivaji Narute, BVSc & AH, MVSc, PhD1,9, Robert McKenna, PhD10, Shahar Keinan, PhD11, Westley Reeves, MD, PhD12, Mark Brantly, MD, PhD13, Carl Pepine, MD, FACC14 and Grant McFadden, PhD1 1Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe AZ, USA 2Saint Josephs Hospital, Dignity Health Phoenix, Phoenix, AZ, USA 3NIH/ NIDDK, Bethesda MD, USA 4Zydus Research Centre, Ahmedabad, India 5Department of tumor surgery, The Second Hospital of Lanzhou University, Lanzhou, Gansu, P.R.China 6Beth Israel Deaconess Medical Center, Harvard, Boston, MA, USA 7Interdisciplinary Institute of Indian system of Medicine (IIISM), SRM University, Chennai, Tamil Nadu, India 8MacMaster University, Hamilton, ON, Canada 9Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA 10Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA 11Cloud Pharmaceuticals, Durham, North Carolina, USA 12Division of Rheumatology, University of Florida,
    [Show full text]
  • Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
    pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity.
    [Show full text]
  • Insights Into the Role of Tick Salivary Protease Inhibitors During Ectoparasite–Host Crosstalk
    International Journal of Molecular Sciences Review Insights into the Role of Tick Salivary Protease Inhibitors during Ectoparasite–Host Crosstalk Mohamed Amine Jmel 1,† , Hajer Aounallah 2,3,† , Chaima Bensaoud 1, Imen Mekki 1,4, JindˇrichChmelaˇr 4, Fernanda Faria 3 , Youmna M’ghirbi 2 and Michalis Kotsyfakis 1,* 1 Laboratory of Genomics and Proteomics of Disease Vectors, Biology Centre CAS, Institute of Parasitology, Branišovská 1160/31, 37005 Ceskˇ é Budˇejovice,Czech Republic; [email protected] (M.A.J.); [email protected] (C.B.); [email protected] (I.M.) 2 Institut Pasteur de Tunis, Université de Tunis El Manar, LR19IPTX, Service d’Entomologie Médicale, Tunis 1002, Tunisia; [email protected] (H.A.); [email protected] (Y.M.) 3 Innovation and Development Laboratory, Innovation and Development Center, Instituto Butantan, São Paulo 05503-900, Brazil; [email protected] 4 Faculty of Science, University of South Bohemia in Ceskˇ é Budˇejovice, 37005 Ceskˇ é Budˇejovice, Czech Republic; [email protected] * Correspondence: [email protected] † These authors contributed equally. Abstract: Protease inhibitors (PIs) are ubiquitous regulatory proteins present in all kingdoms. They play crucial tasks in controlling biological processes directed by proteases which, if not tightly regulated, can damage the host organism. PIs can be classified according to their targeted proteases or their mechanism of action. The functions of many PIs have now been characterized and are showing clinical relevance for the treatment of human diseases such as arthritis, hepatitis, cancer, AIDS, and cardiovascular diseases, amongst others. Other PIs have potential use in agriculture as insecticides, anti-fungal, and antibacterial agents.
    [Show full text]
  • Competitive Inhibition That Barrier, As We Shall See
    Chapter 4 Catalysis In living systems, speed is everything. Providing the reaction speeds necessary to support life are the catalysts, mostly in the form of enzymes. Catalysis Introduction Introduction Activation Energy General Mechanisms of Action If there is a magical component to life, an argument can surely be made for it Substrate Binding being catalysis. Thanks to catalysis, reactions that could take hundreds of years Enzyme Flexibility to complete in the “real world,” occur in seconds in the presence of a catalyst. Active Site Chymotrypsin Chemical catalysts, like platinum, speed reactions, but enzymes (which are simply Enzyme Parameters super-catalysts with a twist) put chemical catalysts to shame. To understand VMAX & KCAT enzymatic catalysis, we must first understand energy. In Chapter 2, we noted the KM tendency for processes to move in the direction of lower energy. Chemical Perfect Enzymes Lineweaver-Burk Plots reactions follow this universal trend, but they often have a barrier in place that Enzyme Inhibition must be overcome. The secret to catalytic action is reducing the magnitude of Competitive Inhibition that barrier, as we shall see. No Effect On VMAX Increased KM Non-Competitive Inhibition Uncompetitive Inhibition Suicide Inhibition Control of Enzymes Allosterism Covalent Control of Enzymes Other Controls of Enzymes Ribozymes Enzyme Rate Enhancements 81 Activation Energy Another feature to note about catalyzed reactions is Click HERE, HERE, and HERE for The figure below schematically depicts the energy changes that the reduced energy barrier Kevin’s Catalytic Mechanism occur during the progression of a simple reaction. In the figure, lectures on YouTube (also called the activation the energy differences during the reaction are compared for a energy or free energy of catalyzed (plot on the right) and an uncatalyzed reaction (plot on activation) to reach the transition state of the catalyzed reaction.
    [Show full text]
  • Optimizing Defence, Counter-Defence and Counter-Counter Defence in Parasitic and Trophic Interactions – a Modelling Study
    1 Optimizing defence, counter-defence and counter-counter defence in parasitic and trophic interactions – A modelling study Stefan Schuster1*, Jan Ewald1,2, Thomas Dandekar2, Sybille Dühring1 1Dept. of Bioinformatics, Friedrich Schiller University of Jena Ernst-Abbe-Platz 2, 07743 Jena, Germany 2Dept. of Bioinformatics, Biocenter Julius Maximilian University of Würzburg Am Hubland, 97074 Würzburg *Corresponding author, e-mail: [email protected] Abstract In host-pathogen interactions, often the host (attacked organism) defends itself by some toxic compound and the parasite, in turn, responds by producing an enzyme that inactivates that compound. In some cases, the host can respond by producing an inhibitor of that enzyme, which can be considered as a counter-counter defence. An example is provided by cephalosporins, β-lactamases and clavulanic acid (an inhibitor of β-lactamases). Here, we tackle the question under which conditions it pays, during evolution, to establish a counter- counter defence rather than to intensify or widen the defence mechanisms. We establish a mathematical model describing this phenomenon, based on enzyme kinetics for competitive inhibition. We use an objective function based on Haber’s rule, which says that the toxic effect is proportional to the time integral of toxin concentration. The optimal allocation of defence and counter-counter defence can be calculated in an analytical way despite the nonlinearity in the underlying differential equation. The calculation provides a threshold value for the dissociation constant of the inhibitor. Only if the inhibition constant is below that threshold, that is, in the case of strong binding of the inhibitor, it pays to have a counter-counter defence.
    [Show full text]
  • Bsc Chemistry
    Subject Chemistry Paper No and Title 16, Bio-organic and Biophysical Chemistry Module No and Title 30, Enzymes as targets or drug design Module Tag CHE_P16_M30 Chemistry PAPER No. : 16, Bioorganic and biophysical chemistry MODULE No. : 30, Enzymes as targets of drug design TABLE OF CONTENTS 1. Learning outcomes 2. Why Enzymes as Drug Targets? 3. Enzyme structure and Catalysis 4. Concept of Enzyme Inhibition 5. Types of Enzyme Inhibition 5.1. Nonspecific Inhibitors 5.2. Specific Inhibitors 6. Summary Chemistry PAPER No. : 16, Bioorganic and biophysical chemistry MODULE No. : 30, Enzymes as targets of drug design 1. Learning outcomes After studying this module you shall be able to: Know about enzymes as drug targets Learn about enzyme structure and catalysis Know the concept of enzyme inhibition Understand the different types of enzyme inhibition 2. Introduction 2.1 Why Enzymes as Drug Targets? Medicine in twenty first century has become a science in which drug molecules are directed against the macromolecules. Enzymes hold a prominent position among the biological macromolecules that can be used as drug targets. Some features of enzyme structures and reaction pathways which make them attractive and primary target for drug action are as follows They play an essential role in biological life processes and pathophysiology The structures of active sites of enzymes and the ligand binding pockets are highly amenable for high affinity interactions with small drug like molecules Presence of potential allosteric sites Conformational variations in the binding sites Can be directly used as a therapeutic agent 3. Enzyme structure and catalysis Enzymes are biological catalysts as well as can act as receptors by acting with the substrates.
    [Show full text]
  • Imexon and Gemcitabine: Mechanisms of Synergy Against Human Pancreatic Cancer
    Imexon and Gemcitabine: Mechanisms of Synergy against Human Pancreatic Cancer Item Type text; Electronic Dissertation Authors Roman, Nicholas Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 02/10/2021 18:39:06 Link to Item http://hdl.handle.net/10150/194494 IMEXON AND GEMCITABINE: MECHANISMS OF SYNERGY AGAINST HUMAN PANCREATIC CANCER by NICHOLAS ORDUÑO ROMÁN _________________________ A Dissertation Submitted to the Faculty of the COMMITTEE ON PHARMACOLOGY AND TOXICOLOGY (GRADUATE) In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY In the Graduate College THE UNIVERSITY OF ARIZONA 2 0 0 5 2 THE UNIVERSITY OF ARIZONA GRADUATE COLLEGE As members of the Dissertation Committee, we certify that we have read the disser tation prepared by Nicholas Ordu ño Rom án entitled Imexon and Gemcitabine: Mechanisms of Synergy against Human Pancreatic Cancer and recommend that it be accepted as fulfilling the dissertation requirement for the Degree of Doctor of Philosophy _____________________________________ ___________________________ Date:_______________ Robert T. Dorr, Ph.D. 4/12/05 _________ _______________________________________________________ Date:_______________ Terrence J. Monks. Ph.D. 4/12/05 _____ ___________________________________________________________ Date:_______________ Nathan J. Cherrington, Ph.D. 4/12/05 __________________________________________ ______________________ Date:_______________ Garth Powis, D. Phil. 4/12/05 ________ __ ______________________________________________________ Date:_______________ Terry H. Landowski, Ph.D. 4/12/05 Final approval and acceptance of this dissertation is contingent upon the candidate’s submission of the final copies of the dissertatio n to the Graduate College.
    [Show full text]
  • Identification of Regulatory Mechanisms of the Hepatic
    Available online at www.sciencedirect.com Computers and Chemical Engineering 32 (2008) 356–369 Identification of regulatory mechanisms of the hepatic response to thermal injury E. Yang a, T.J. Maguire a, M.L. Yarmush a, F. Berthiaume b, I.P. Androulakis a,∗ a Biomedical Engineering Department, Rutgers University, Piscataway, NJ, USA b Center for Engineering in Medicine/Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, MA, USA Received 30 October 2006; received in revised form 11 February 2007; accepted 13 February 2007 Available online 25 February 2007 Abstract The purpose of this paper is to evaluate the hypothesis that a systems biology approach can be developed such that a set of transcription factors, relevant to burn-induced inflammatory response can be identified and modulated to control the host response. We explore a novel method for identifying coherent and informative expression motifs and we subsequently determine conserved transcription factor binding sites for the sub-sets of co-expressed genes. The responses are rationalized in the context of burn-induced inflammation and the putative transcription factors are rationalized in the context of intervention targets for controlling gene expression. © 2007 Published by Elsevier Ltd. Keywords: Gene expression; Burn; Inflammation; Transcritpion factors 1. Introduction to thermal injury predispose to the later hypermetabolic state would make it possible to define points of intervention by which Deep thermal injury over greater than 20 percent of the total such outcomes can be avoided. body surface area is one of the most severe forms of trauma. The response to burn injury and trauma results from a com- Following the early acute phase response dealing with the initial plex interplay between inflammation caused by the initial injury injury and shock (Carter, Tompkins, Yarmush, Walker, & Burke, and hypermetabolism.
    [Show full text]
  • Reversible and Mechanism-Based Irreversible Inhibitor Studies on Human Steroid Sulfatase and Protein Tyrosine Phosphatase 1B
    Reversible and Mechanism-Based Irreversible Inhibitor Studies on Human Steroid Sulfatase and Protein Tyrosine Phosphatase 1B by F. Vanessa Ahmed A thesis presented to the University of Waterloo in fulfilment of the thesis requirement for the degree of Doctor of Philosophy in Chemistry Waterloo, Ontario, Canada, 2009 © F. Vanessa Ahmed 2009 Author’s Declaration I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including any required final revisions, as accepted by my examiners. I understand that my thesis may be made electronically available to the public. ii Abstract The development of reversible and irreversible inhibitors of steroid sulfatase (STS) and protein tyrosine phosphatase 1B (PTP1B) is reported herein. STS belongs to to the aryl sulfatase family of enzymes that have roles in diverse processes such as hormone regulation, cellular degradation, bone and cartilage development, intracellular communication, and signalling pathways. STS catalyzes the desulfation of sulfated steroids which are the storage forms of many steroids such as the female hormone estrone. Its crucial role in the regulation of estrogen levels has made it a therapeutic target for the treatment of estrogen-dependent cancers. Estrone sulfate derivatives bearing 2- and 4- mono- and difluoromethyl substitutions were examined as quinone methide-generating suicide inhibitors of STS with the goal of developing these small molecules as activity- based probes for proteomic profiling of sulfatases. Kinetic studies suggest that inhibition by the monofluoro derivatives is a result of a quinone methide intermediate that reacts with active-site nucleophiles. However, the main inhibition pathway of the 4- difluoromethyl derivative involved an unexpected process in which initially formed quinone methide diffuses from the active site and decomposes to an aldehyde in solution which then acts as a potent, almost irreversible STS inhibitor.
    [Show full text]
  • Cefoxitin, N-Formimidoyl Thienamycin, Clavulanic
    1594 THE JOURNAL OF ANTIBIOTICS NOV. 1982 CEFOXITIN, N-FORMIMIDOYL THIENAMYCIN, CLAVULANIC ACID, AND PENICILLANIC ACID SULFONE AS SUICIDE INHIBITORS FOR DIFFERENT TYPES OF ~-LACTAMASES PRODUCED BY GRAM-NEGATIVE BACTERIA TETSUO SAWAI and KIKUO TSUKAMOTO Faculty of Pharmaceutical Sciences, Chiba University, Chiba, Japan (Received for publication July 30, 1982) Cefoxitin, N-formimidoyl thienamycin (MK0787), clavulanic acid, and penicillanic acid sulfone (CP45,899) were studied to determine their potency as suicide inhibitors of three very different kinds of Vii-lactamases produced by Gram-negative bacteria: type Ib penicillinase (TEM-2 type), a typical cephalosporinase (the enzyme of Proteus morganii), and a cephalo- sporinase with broad substrate specificity (the enzyme of Proteus vulgaris). All these ~-lactams were confirmed to be quite stable to the three 19-lactamases. The absolute values of the turn- over numbers (kcat) for these enzyme-catalyzed hydrolyses were determined, the values ranged from 0.25 minute-1 to 660 minute-1. All the j3-lactams studied, except cefoxitin, acted as suicide inhibitors of the typical cephalosporinase. Although cefoxitin did not exhibit such an effect, it was a powerful competitive inhibitor of this enzyme. Although the four j3-lactams acted as suicide inhibitors of the P. vulgaris cephalosporinase, the inactivated enzyme partially regained its activity after removing the effect of the free inhibitor. Type lb penicillinase was also inactivated by the four p-lactams, and the activity of the inactivated enzyme, except in the case of cefoxitin, was partially restored. The rate constants for enzyme inactivation or reacti- vation were calculated and are presented. The information obtained from this study suggests that the catalytic center of the P.
    [Show full text]
  • Chapter 8. Enzymes: Basic Concepts and Kinetics
    CHAPTER 8. ENZYMES: BASIC CONCEPTS AND KINETICS coelenterazine The activity of an enzyme is responsible for the glow of the luminescent jellyfish at left. The enzyme aequorin catalyzes the oxidation of a compound by oxygen in the presence of calcium to release CO2 and light CHAPTER 8. ENZYMES: BASIC CONCEPTS AND KINETICS Introduction . Enzymes are large biological molecules that catalyze chemical transformations . The molecule also mediates the transformation of one form of energy into another . 25% of the genes in the human genome encode enzymes . Catalytic power and specificity – important characteristics . Active site – the place where enzymatic reactions take place CHAPTER 8. ENZYMES: BASIC CONCEPTS AND KINETICS Introduction . Nearly all known enzymes are proteins • RNA can function as a catalyst . Proximity effect – enzymes bring substrates closer together in an optimal orientation . They catalyze reactions by stabilizing transition states 8.1 CATALYTIC POWER AND SPECIFICITY Rate enhancement by enzymes . Enzymes accelerate reactions by factors of as much as a million or more 8.1 CATALYTIC POWER AND SPECIFICITY Substrate specificity . A substrate is a molecule upon which an enzyme acts . Some proteases cleaves specific amide bonds in a peptide . The specificity of an enzyme is due to the precise interaction of the substrate with the enzyme . This precision is a result of the intricate 3D structure of the enzyme protein Fig 8.1 Enzyme specificity. (A) Trypsin cleaves on the carboxyl side of arginine and lysine residues, whereas (B) thrombin cleaves Arg-Gly bonds in particular sequences only 8.1 CATALYTIC POWER AND SPECIFICITY Cofactors . The catalytic activity of enzymes depends on the presence of small molecules termed cofactors .
    [Show full text]
  • Pdf (734.95 K)
    Biochemistry Letters, 11(20) 2016, pages 259-274 Scientific Research & Studies Center-Faculty of Science- Zagazig University- Egypt Biochemistry Letters Journal home page: Interactions of Monoamine Oxidase from Human And Rat Liver Mitochondria with (S)-2-[4-(3-Flouro-Benzyloxy)-Benzylamino]-Propionamide Zakia Ben Ramadan*1 , Keith Tipton2 , Safaa khater3 1-Department of Biochemistry, Faculty of Medicine University of Tripoli-Libya. 2-Department of Biochemistry, Trinity College, Dublin 2, Ireland . 3- Department of Biochemistry, Zagazig University –Egypt. ARTICLE INFO ABSTRACT Article history: Background:The interactions of the anticonvulsant (S)-2-[4- Received : (3-Flouro-Benzyloxy) Benzylamino]- Propionamide (FCE Accepted : 26743) with MAO-A and MAO -B from human and rat liver Available online : mitochondria has been studied. Objective: This compound is an alanine derivative that differs from the parent anticonvulsant Keywords: Monoamine compound, 2-n-pentylamino acetamide in that alaninamide oxidase-A and-B (MAO-A& residue replaces the glycinamide moiety, and in the presence of MAO -B), kinetics of inhibition, a phenyl ring substituted in the para-position by a 3-flouro- (S)-2-[4-(3-flourobenzyloxy)- benzyloxy group. Results: The results indicated that, The Ki benzylamino] propionamide, values for rat and human MAO-A were > 1000 times higher (FCE 26743), Inhibition than their corresponding values for rat and human MAO- Studies. Consistent with the IC50values that showed this compound to be > 1000 times more potent as an inhibitor of MAO-B than of MAO-A of the same species. There was an increase in the strength of inhibition when MAO-B was incubated with this compound. This was confirmed by the extended time-courses studies which showed a rather rapid increase in the degree of inhibition of MAO-B, despite incubation being continued for a total of 4h.
    [Show full text]